Page 3 - Pharma Companies
PLI schemes should focus on firms making pharma products: Bharat Biotech
Production-linked incentive schemes should also focus on companies providing packaging materials and other services in addition to manufacturers of branded pharmaceutical items to reduce import dependence, according to Bharat Biotech Executive Director Sai Prasad. He also emphasised on shifting the focus towards innovative pharmaceuticals products in order to enhance the margins for industry players. "We already have policies like production-linked incentive (PLI) schemes and research-based schemes and these policies are going to be very helpful for the sector... It is our view that such policies should also focus on companies which provide goods and services to the pharma industry," Prasad told PTI in an interaction. The incentives also need to be given to single-use consumer companies, raw material packaging firms and other service providers in the pharmaceutical supply chain, he added. "If the ecosystem is strong only then the branded companies could be strong," Prasad said. He
 "PLI schemes should focus on firms making pharma products: Bharat Biotech")
Mankind Pharma files for IPO, could be second largest among pharma firms
The offer for sale is expected to be anywhere between Rs 5000-5500 crore, say sources
 "Mankind Pharma files for IPO, could be second largest among pharma firms")
SEBI asks pharma companies to disclose details that can impact stock prices
The details that need to be disclosed are new drugs, pending patents, source of raw materials, and new partnerships, among others
 "SEBI asks pharma companies to disclose details that can impact stock prices")
Essential medicines list updated, adds 34 new drugs and drops 26
Medicines to treat diabetes, HIV, TB, contraceptives, hormonal medicines included in National List of Essential Medicines
 "Essential medicines list updated, adds 34 new drugs and drops 26")
NLEM 2022: Analysts see no major impact pharma companies' growth
The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc
 "NLEM 2022: Analysts see no major impact pharma companies' growth")
Pharma body clears Micro Labs of charges of spending Rs 1000 cr on freebies
Indian Pharmaceutical Alliance ethics committee submits report to NPPA
 "Pharma body clears Micro Labs of charges of spending Rs 1000 cr on freebies")
Zenara Pharma launches tablets to treat mild to moderate symptoms of Covid
Zenara Pharma had received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market this product last month
US ranitidine litigation unlikely to impact Indian pharma: Analysts
Sun Pharmaceuticals, Dr Reddy's Laboratories, Perrigo and Teva have agreed to a combined settlement of $5 mn with cancer patient Joseph Bayer
 "US ranitidine litigation unlikely to impact Indian pharma: Analysts")
Bharat Biotech says Phase 3 trial over, intranasal vaccine 'safe'
The Hyderabad-based company claimed that BBV154 is proven to be safe, well-tolerated and immunogenic in the subjects under controlled clinical trials
 "Bharat Biotech says Phase 3 trial over, intranasal vaccine 'safe'")
Pfizer's managing director S Sridhar to take an early retirement
Over the past 14 years, Sridhar has led a number of key leadership positions in Pfizer, including serving as the Chief Financial Officer for a period of eight years
 "Pfizer's managing director S Sridhar to take an early retirement")
Pfizer buying spree continues with $5.4 billion hematology deal
Pfizer also announced in April a smaller acquisition to buy the privately held ReViral Ltd., which is developing a treatment for respiratory syncytial virus
 "Pfizer buying spree continues with $5.4 billion hematology deal")
Dr Reddy's Laboratories inks licensing pact with US' Slayback Pharma
Dr Reddy's Laboratories on Saturday said it has entered into a pact with US-based Slayback Pharma to acquire rights of a medication to relieve redness of the eyes
 "Dr Reddy's Laboratories inks licensing pact with US' Slayback Pharma")
Syngene International signs 10-year agreement with US-based firm Zoetis
Librela or bedinvetmab has already been launched in Europe and the UK, and has won 'Best new companion animal product' by IHS Markit Connect in 2021
 "Syngene International signs 10-year agreement with US-based firm Zoetis")
Glenmark nasal spray cuts down viral load of Covid by 94% in 24 hrs
Glenmark had conducted the study on 306 vaccinated and unvaccinated adults with symptomatic mild Covid-19 disease across 20 clinical trial sites in India
 "Glenmark nasal spray cuts down viral load of Covid by 94% in 24 hrs")
Results preview: Pharma margins likely to remain under pressure in Q1
Hospitals back to normalcy; tough road ahead for diagnostics
 "Results preview: Pharma margins likely to remain under pressure in Q1")
Dolo-650 manufacturer faces raids by I-T dept in tax evasion case
A team of more than 20 officers associated with the I-T dept conducted the raids on the pharma company's Race Course Road office
 "Dolo-650 manufacturer faces raids by I-T dept in tax evasion case")
Research-linked incentive scheme in works for pharmaceutical industry
15% turnover investment in research could make companies eligible for the scheme
 "Research-linked incentive scheme in works for pharmaceutical industry")
DCGI approves indigenous mRNA Covid jab for emergency use in adults: Report
It is for the first time ever that Covid-19 vaccine remains stable during storage even at 2-8 degrees Celsius
 "DCGI approves indigenous mRNA Covid jab for emergency use in adults: Report")
Glenmark acquires Wockhardt's key OTC brands in US for undisclosed sum
Deal includes approved ANDAs for famotidine tablets, used in treatment and prevention of ulcers stomach and intestinal ulcers
Glenmark Pharmaceuticals acquires certain OTC drugs from Wockhardt in US
Glenmark said its current portfolio consists of 175 products authorised for distribution in the US market and 48 ANDAs pending approval with the USFDA
